Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Company Deals

UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases

Fineline Cube Jun 18, 2026
Company Deals

Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline

Fineline Cube Jun 18, 2026
Company Deals

Xunfei Healthcare Partners with Sinar Mas Group to Deploy AI Medical Solutions Across Indonesia

Fineline Cube Jun 18, 2026
Company Deals

Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline

Fineline Cube Jun 18, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

CSPC Pharmaceutical’s Cosentyx Biosimilar Accepted for NMPA Review in China’s Competitive IL-17A Market

Fineline Cube Jun 22, 2026
Company Drug

CSPC Pharmaceutical Secures FDA Clearance for SYHX2008 Octreotide Biosimilar Clinical Trials in US Market

Fineline Cube Jun 22, 2026
Company

Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results

Fineline Cube Sep 29, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has released its 2022 interim report, recording RMB 2.24...

Company Drug

Lepu Biotechnology’s MRG003 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma

Fineline Cube Sep 29, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received Breakthrough Therapy...

Company Drug

Lepu Biotechnology’s PD-1 Inhibitor HX008 Gains New Indication Approval

Fineline Cube Sep 29, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received another indication...

Company Drug

Neurophth Biotechnology Doses First Patient in Phase III Trial for NR082

Fineline Cube Sep 29, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that the first patient has been...

Company Drug

Bio-Thera Solutions Completes Phase I Study for COVID-19 Antibody BAT2022

Fineline Cube Sep 29, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced the completion of all dosage groups (from 100...

Company

Allergan Aesthetics Opens Shanghai Innovation Center for Medical Aesthetics

Fineline Cube Sep 29, 2022

Allergan Aesthetics, a division of AbbVie, has officially opened its Shanghai innovation center, marking a...

Company

Biosyngen to Establish Cell Therapy GMP Facility in Singapore

Fineline Cube Sep 29, 2022

Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at...

Company

Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges

Fineline Cube Sep 29, 2022

China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85...

Company Medical Device

Parexel Opens Clinical Study Supply Chain Center in Suzhou

Fineline Cube Sep 29, 2022

US-based contract research organization (CRO) Parexel has announced the opening of its clinical study supply...

Company Drug

Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043

Fineline Cube Sep 29, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has...

Company Drug

Arctic Vision Enrolls First Patient in Phase III Study for ARVN002

Fineline Cube Sep 29, 2022

China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a...

Company Deals

3D Medicines Partners with Denfo Medical for Cancer Therapy Development

Fineline Cube Sep 29, 2022

China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group,...

Company Deals

Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278

Fineline Cube Sep 29, 2022

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with...

Company Deals

Insight Lifetech Raises Funds for Cardiovascular Solutions Expansion

Fineline Cube Sep 29, 2022

Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured...

Company

Santen Pharmaceutical Launches New Plant Construction in Suzhou

Fineline Cube Sep 28, 2022

Japan-based Santen Pharmaceutical Co. has launched the construction of a new plant in Suzhou, Jiangsu...

Company Drug

Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma

Fineline Cube Sep 28, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and...

Company Deals

Eureka Biotech Partners with Ucello for Universal CAR-T Cell Therapy Development

Fineline Cube Sep 28, 2022

Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with...

Company Deals

Merck Sharp & Dohme Partners with Sinopharm for Molnupiravir in China

Fineline Cube Sep 28, 2022

US-based Merck Sharp & Dohme (MSD, NYSE: MRK) has entered into a cooperation framework agreement...

Company Drug

NMPA Releases 59th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Sep 28, 2022

The National Medical Products Administration (NMPA) has released the 59th batch of reference drugs for...

Company

SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results

Fineline Cube Sep 28, 2022

SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private...

Posts pagination

1 … 639 640 641 … 686

Recent updates

  • CSPC Pharmaceutical’s Cosentyx Biosimilar Accepted for NMPA Review in China’s Competitive IL-17A Market
  • CSPC Pharmaceutical Secures FDA Clearance for SYHX2008 Octreotide Biosimilar Clinical Trials in US Market
  • Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)
  • Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success
  • Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical’s Cosentyx Biosimilar Accepted for NMPA Review in China’s Competitive IL-17A Market

Company Drug

CSPC Pharmaceutical Secures FDA Clearance for SYHX2008 Octreotide Biosimilar Clinical Trials in US Market

Others

Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)

Company Drug

Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.